Estee Lauder Forecasts Annual Profit Below Estimates

Alvotech, a global biotechnology company, has appointed Patrik Ling as VP of Investor Relations Scandinavia. With over 25 years of experience in the life science industry, Ling previously worked as a Senior Equity Analyst at DNB Carnegie, where he covered life science companies, including Alvotech. He will be based in Stockholm and will focus on expanding Alvotech's shareholder base in Scandinavia.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines, has appointed Patrik Ling as Vice President of Investor Relations Scandinavia. Ling, who will be based in Stockholm, brings over 25 years of experience in the life-science industry [1].

Ling most recently served as Senior Equity Analyst at DNB Carnegie, where he covered life science companies, including Alvotech. His career spans both pharmaceutical and financial sectors, with roles in marketing, sales, portfolio management, and equity analysis. This diverse background positions him well to expand Alvotech's shareholder base in Scandinavia and strengthen its position as a leading Nordic life science company [1].

Róbert Wessman, chairman and CEO of Alvotech, expressed his pleasure at having Ling on board. "It is a great pleasure to have Patrik on board, as he’s been following Alvotech closely over the years and is a highly respected expert within the life science industry in Scandinavia. Patrik’s background in both pharma and finance, will be a great asset to our team as we continue to broaden our shareholder base in Scandinavia and affirm Alvotech’s role as a leading life science company in the Nordics," said Wessman [1].

Ling is excited about the opportunity to engage with Scandinavian investors and help them understand Alvotech's strengths and value proposition. "This is a truly exciting time to join Alvotech, with its expanding portfolio of products in the market and in development, supported by a new base of R&D operations in Sweden. Biosimilars play an important role in meeting the growing demand for high-quality biologics and controlling the escalating cost of healthcare. I look forward to engaging with Scandinavian investors, helping them to better understand Alvotech’s strengths and value proposition," said Ling [1].

Alvotech, founded by Róbert Wessman, is focused on delivering high-quality, cost-effective biosimilar medicines. With two biosimilars already approved and marketed in multiple global markets, and a robust development pipeline, Alvotech aims to be a global leader in the biosimilar space [1].

References:
[1] https://www.stocktitan.net/news/ALVO/alvotech-appoints-patrik-ling-as-vp-of-investor-relations-5rd2v9msjxt8.html
[2] https://finance.yahoo.com/news/alvotech-appoints-patrik-ling-vp-100500538.html